{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:00:40Z","timestamp":1781233240965,"version":"3.54.1"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NCCS Cancer Fund"},{"name":"SingHealth Duke-NUS Academic Medicine Centre"},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/TA\/0061\/2017"],"award-info":[{"award-number":["NMRC\/TA\/0061\/2017"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2021-0150_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Peritoneal cancer index (PCI) score is a common prognostication tool in peritoneal metastases (PM). We hypothesize that the distribution of PCI score and involvement of specific regions affects survival and morbidity outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0150_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data was collected from a prospective database of patients who underwent CRS and HIPEC for PM at the National Cancer Centre Singapore. We evaluate the relationship between PCI, PCI distribution, and survival and morbidity outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0150_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and fifty-two patients underwent CRS and HIPEC with a median PCI score of nine (range 0\u201331). Median overall survival (OS) and progression free survival (PFS) were 43 and 17\u00a0months, respectively. Region six (pelvis) was most commonly involved and had the highest frequency of heavy disease burden. Presence of PM in the lower abdomen, flanks, and small bowel were associated with poorer OS (p=0.01, 0.03, &lt;0.001) and PFS (p=0.04, 0.02, &lt;0.001). Involvement of porta hepatitis predicted poorer OS but not PFS (p=0.03). Involvement of the gastric\u00a0antrum resulted in higher rates of postoperative complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2021-0150_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The pattern of PCI distribution may be associated with varying survival and morbidity outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2021-0150","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T04:38:03Z","timestamp":1650861483000},"page":"95-102","source":"Crossref","is-referenced-by-count":5,"title":["Implications of peritoneal cancer index distribution on patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy"],"prefix":"10.1515","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-5755","authenticated-orcid":false,"given":"Jolene Si Min","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Surgery Academic Medical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Oncology Academic Medical Program, Duke-NUS Medical School , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0672-9041","authenticated-orcid":false,"given":"Grace Hwei Ching","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Hui Xian","family":"Cheok","sequence":"additional","affiliation":[{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4573-7738","authenticated-orcid":false,"given":"Chin-Ann Johnny","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Surgery Academic Medical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Oncology Academic Medical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5540-2646","authenticated-orcid":false,"given":"Claramae Shulyn","family":"Chia","sequence":"additional","affiliation":[{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Surgery Academic Medical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Oncology Academic Medical Program, Duke-NUS Medical School , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3984-8108","authenticated-orcid":false,"given":"Melissa Ching Ching","family":"Teo","sequence":"additional","affiliation":[{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore , Singapore , Singapore"},{"name":"Department of Sarcoma , Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Surgery Academic Medical Program, Duke-NUS Medical School , Singapore , Singapore"},{"name":"SingHealth Duke-NUS Oncology Academic Medical Program, Duke-NUS Medical School , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"2025120909241449231_j_pp-2021-0150_ref_001","doi-asserted-by":"crossref","unstructured":"Jacquet, P, Sugarbaker, PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2025120909241449231_j_pp-2021-0150_ref_002","doi-asserted-by":"crossref","unstructured":"Portilla, AG, Shigeki, K, Dario, B, Marcello, D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol 2008;98:228\u201331. https:\/\/doi.org\/10.1002\/jso.21068.","DOI":"10.1002\/jso.21068"},{"key":"2025120909241449231_j_pp-2021-0150_ref_003","doi-asserted-by":"crossref","unstructured":"Swellengrebel, HA, Zoetmulder, FA, Smeenk, RM, Antonini, N, Verwaal, VJ. Quantitative intra-operative assessment of peritoneal carcinomatosis\u00a0\u2013 a comparison of three prognostic tools. Eur\u00a0J\u00a0Surg Oncol 2009;35:1078\u201384. https:\/\/doi.org\/10.1016\/j.ejso.2009.02.010.","DOI":"10.1016\/j.ejso.2009.02.010"},{"key":"2025120909241449231_j_pp-2021-0150_ref_004","doi-asserted-by":"crossref","unstructured":"Harmon, RL, Sugarbaker, PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005;2:3. https:\/\/doi.org\/10.1186\/1477-7800-2-3.","DOI":"10.1186\/1477-7800-2-3"},{"key":"2025120909241449231_j_pp-2021-0150_ref_005","doi-asserted-by":"crossref","unstructured":"Tan, GHC, Chia, CS, Tan, SH, Soo, KC, Teo, MCC. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Int J Clin Oncol 2018;23:989\u201398. https:\/\/doi.org\/10.1007\/s10147-018-1301-8.","DOI":"10.1007\/s10147-018-1301-8"},{"key":"2025120909241449231_j_pp-2021-0150_ref_006","doi-asserted-by":"crossref","unstructured":"Deo, S, Ray, M, Bansal, B, Bhoriwal, S, Bhatnager, S, Garg, R, et al.. Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases. World J Surg Oncol 2021;19:164. https:\/\/doi.org\/10.1186\/s12957-021-02276-5.","DOI":"10.1186\/s12957-021-02276-5"},{"key":"2025120909241449231_j_pp-2021-0150_ref_007","doi-asserted-by":"crossref","unstructured":"Shang, A, Wang, S, Yang, Y, Li, L, Zhao, Z, Li, D, et al.. Effect and safety of intraoperative intraperitoneal chemotherapy on patients suffering from colorectal cancer. World J Surg Oncol 2021;19:84. https:\/\/doi.org\/10.1186\/s12957-021-02197-3.","DOI":"10.1186\/s12957-021-02197-3"},{"key":"2025120909241449231_j_pp-2021-0150_ref_008","doi-asserted-by":"crossref","unstructured":"Gasimli, K, Braicu, EI, Richter, R, Chekerov, R, Sehouli, J. Prognostic and predictive value of the peritoneal cancer index in primary advanced epithelial ovarian cancer patients after complete cytoreductive surgery: study of tumor bank ovarian cancer. Ann Surg Oncol 2015;22:2729\u201337. https:\/\/doi.org\/10.1245\/s10434-014-4329-7.","DOI":"10.1245\/s10434-014-4329-7"},{"key":"2025120909241449231_j_pp-2021-0150_ref_009","doi-asserted-by":"crossref","unstructured":"Tentes, AAK, Tripsiannis, G, Markakidis, SK, Karanikiotis, CN, Tzegas, G, Georgiadis, G, et al.. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003;29:69\u201373. https:\/\/doi.org\/10.1053\/ejso.2002.1380.","DOI":"10.1053\/ejso.2002.1380"},{"key":"2025120909241449231_j_pp-2021-0150_ref_010","doi-asserted-by":"crossref","unstructured":"Meyers, MA. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med 1973;119:198\u2013206. https:\/\/doi.org\/10.2214\/ajr.119.1.198.","DOI":"10.2214\/ajr.119.1.198"},{"key":"2025120909241449231_j_pp-2021-0150_ref_011","doi-asserted-by":"crossref","unstructured":"Carmignani, CP, Sugarbaker, TA, Bromley, CM, Sugarbaker, PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465\u201372. https:\/\/doi.org\/10.1023\/a:1023791229361.","DOI":"10.1023\/A:1023791229361"},{"key":"2025120909241449231_j_pp-2021-0150_ref_012","doi-asserted-by":"crossref","unstructured":"Trilling, B, Brind\u2019Amour, A, Hamad, R, Tremblay, J-F, Dub\u00e9, P, Mitchell, A, et al.. Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index. World J Surg Oncol 2021;19:60. https:\/\/doi.org\/10.1186\/s12957-021-02171-z.","DOI":"10.1186\/s12957-021-02171-z"},{"key":"2025120909241449231_j_pp-2021-0150_ref_013","doi-asserted-by":"crossref","unstructured":"Paredes, AZ, Guzman-Pruneda, FA, Abdel-Misih, S, Hays, J, Dillhoff, ME, Pawlik, TM, et al.. Perioperative morbidity of gastrectomy during CRS-HIPEC: an ACS-NSQIP analysis. J Surg Res 2019;241:31\u20139. https:\/\/doi.org\/10.1016\/j.jss.2019.03.036.","DOI":"10.1016\/j.jss.2019.03.036"},{"key":"2025120909241449231_j_pp-2021-0150_ref_014","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH, Chang, D, Jelinek, JS. Concerning CT features predict outcome of treatment in patients with malignant peritoneal mesothelioma. Eur J Surg Oncol 2021;47:2212\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2021.04.012.","DOI":"10.1016\/j.ejso.2021.04.012"},{"key":"2025120909241449231_j_pp-2021-0150_ref_015","doi-asserted-by":"crossref","unstructured":"Cascales Campos, P, Gil, J, Parrilla, P. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. Eur J Surg Oncol 2014;40:970\u20135. https:\/\/doi.org\/10.1016\/j.ejso.2013.08.013.","DOI":"10.1016\/j.ejso.2013.08.013"},{"key":"2025120909241449231_j_pp-2021-0150_ref_016","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43:S15\u201325. https:\/\/doi.org\/10.1007\/s002800051093.","DOI":"10.1007\/s002800051093"},{"key":"2025120909241449231_j_pp-2021-0150_ref_017","doi-asserted-by":"crossref","unstructured":"Dindo, D, Demartines, N, Clavien, PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"2025120909241449231_j_pp-2021-0150_ref_018","doi-asserted-by":"crossref","unstructured":"Teo, MCC, Tan, GHC, Tham, CK, Lim, C, Soo, KC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. Ann Surg Oncol 2013;20:2968\u201374. https:\/\/doi.org\/10.1245\/s10434-013-2947-0.","DOI":"10.1245\/s10434-013-2947-0"},{"key":"2025120909241449231_j_pp-2021-0150_ref_019","doi-asserted-by":"crossref","unstructured":"Wong, JSM, Tan, GHC, Chia, CS, Ong, J, Ng, WY, Teo, MCC. The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2020;18:10. https:\/\/doi.org\/10.1186\/s12957-020-1784-4.","DOI":"10.1186\/s12957-020-1784-4"},{"key":"2025120909241449231_j_pp-2021-0150_ref_020","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Management of peritoneal-surface malignancy: the surgeon\u2019s role. Langenbeck\u2019s Arch Surg 1999;384:576\u201387. https:\/\/doi.org\/10.1007\/s004230050246.","DOI":"10.1007\/s004230050246"},{"key":"2025120909241449231_j_pp-2021-0150_ref_021","doi-asserted-by":"crossref","unstructured":"Lemoine, L, Sugarbaker, P, Van der Speeten, K. Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum. World J Gastroenterol 2016;22:7692\u2013707. https:\/\/doi.org\/10.3748\/wjg.v22.i34.7692.","DOI":"10.3748\/wjg.v22.i34.7692"},{"key":"2025120909241449231_j_pp-2021-0150_ref_022","doi-asserted-by":"crossref","unstructured":"Asmar, AE, Bendavides, M, Moreau, M, Hendlisz, A, Deleporte, A, Khalife, M, et al.. Postoperative C-reactive protein kinetics predict postoperative complications in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. World J Surg Oncol 2020;18:311. https:\/\/doi.org\/10.1186\/s12957-020-02081-6.","DOI":"10.1186\/s12957-020-02081-6"},{"key":"2025120909241449231_j_pp-2021-0150_ref_023","doi-asserted-by":"crossref","unstructured":"Sugarbaker, TA, Chang, D, Koslowe, P, Sugarbaker, PH. Pathobiology of peritoneal carcinomatosis from ovarian malignancy. Cancer Treat Res 1996;81:63\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1245-1_7.","DOI":"10.1007\/978-1-4613-1245-1_7"},{"key":"2025120909241449231_j_pp-2021-0150_ref_024","unstructured":"Yawar, B, Babar, S, Imaad Ur, R, Sana, F, Javed, F, Chaudhary, MY. Multidetector CT patterns of peritoneal involvement in patients with abdominopelvic malignancies. J Coll Physicians Surg Pak 2015;25:399\u2013402."},{"key":"2025120909241449231_j_pp-2021-0150_ref_025","doi-asserted-by":"crossref","unstructured":"Woodward, PJ, Hosseinzadeh, K, Saenger, JS. From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics 2004;24:225\u201346. https:\/\/doi.org\/10.1148\/rg.241035178.","DOI":"10.1148\/rg.241035178"},{"key":"2025120909241449231_j_pp-2021-0150_ref_026","doi-asserted-by":"crossref","unstructured":"Spiliotis, J, Kalles, V, Kyriazanos, I, Terra, A, Prodromidou, A, Raptis, A, et al.. CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: the small-bowel PCI score as a predictor of survival. Pleura Peritoneum 2019;4:20190018. https:\/\/doi.org\/10.1515\/pp-2019-0018.","DOI":"10.1515\/pp-2019-0018"},{"key":"2025120909241449231_j_pp-2021-0150_ref_027","doi-asserted-by":"crossref","unstructured":"Zhou, S, Jiang, Y, Liang, J, Pei, W, Zhou, Z. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy. World J Surg Oncol 2021;19:151. https:\/\/doi.org\/10.1186\/s12957-021-02255-w.","DOI":"10.1186\/s12957-021-02255-w"},{"key":"2025120909241449231_j_pp-2021-0150_ref_028","doi-asserted-by":"crossref","unstructured":"Singh, B, Fisher, OM, Singh, G, Lansom, J, Bock, M, Kozman, M, et al.. Short- and long-term outcomes of patients requiring gastrectomy during cytoreductive surgery and intraperitoneal chemotherapy for lower-gastrointestinal malignancies: a propensity score-matched analysis. Ann Surg Oncol 2019;26:3627\u201335. https:\/\/doi.org\/10.1245\/s10434-019-07510-9.","DOI":"10.1245\/s10434-019-07510-9"},{"key":"2025120909241449231_j_pp-2021-0150_ref_029","doi-asserted-by":"crossref","unstructured":"Jiao, J, Li, C, Yu, G, Zhang, L, Shi, X, Yan, J, et al.. Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites. World J Surg Oncol 2020;18:180. https:\/\/doi.org\/10.1186\/s12957-020-01956-y.","DOI":"10.1186\/s12957-020-01956-y"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0150\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0150\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:01:21Z","timestamp":1765278081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2021-0150\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,15]]},"published-print":{"date-parts":[[2022,6,3]]}},"alternative-id":["10.1515\/pp-2021-0150"],"URL":"https:\/\/doi.org\/10.1515\/pp-2021-0150","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]}}}